Summary. Background: Multiple electrode aggregometry (MEA) measures changes in electrical impedance caused by platelet aggregation in whole blood. This approach is faster, more convenient and offers the advantage over light transmission aggregometry (LTA) of assessing platelet function in whole blood and reducing preanalytical errors associated with preparation of platelet-rich plasma (PRP). Several studies indicate the utility of this method in assessing platelet inhibition in individuals taking antiplatelet agents (e.g. aspirin and clopidogrel). Objective: Our current study sought to evaluate the ability of MEA in diagnosing patients with mild bleeding disorders by comparison with light transmission lumi-aggregometry (lumi-LTA). Methods: Forty healthy subjects and 109 patients with a clinical diagnosis of a mild bleeding disorder were recruited into the UK Genotyping and Phenotyping of Platelets study (GAPP, ISRCTN 77951167). MEA was performed on whole blood using one or two
Introduction
Individuals with inherited platelet function disorders (PFDs) comprise a heterogeneous group characterized by impaired platelet function and variable bleeding symptoms, which in some cases can be life threatening. Characterization of individual platelet function defects is crucial for optimal treatment and management as even frequent minor bleeding episodes can have a significant impact on quality of life. Diagnosis of severe forms of PFDs, such as Glanzmann thrombasthenia (GT) and Bernard-Soulier syndrome (BSS), is less challenging because bleeding symptoms are not only usually identified early in life, but laboratory tests are often straightforward because of the absence of aggregation and ristocetin-induced agglutination, respectively [1, 2] , and lack of expression of glycoproteins measured by flow cytometry [3] . In contrast, diagnosis of the milder forms of PFD is complex and challenging. Bleeding symptoms may not manifest in early age because of the absence of hemostatic challenges such as surgery, injury and childbirth. Additionally, many PFDs exhibit unclear penetrance and symptoms are similar to other hemostatic disorders, including type 1 von Willebrand disease (VWD) [4] .
A number of tests are currently available to assess platelet function. The most commonly used is light transmission aggregometry (LTA), which was first described by Born over 50 years ago [5] . The test measures the change in light transmission in real time when agonists are added to platelet-rich plasma (PRP) or washed platelets. A typical panel of agonists includes ADP, collagen, arachidonic acid, adrenaline, PAR-1 peptide, U46619 and ristocetin [6] . The nature of the response is dependent on the agonist used, its concentration and the role of the feedback agonists ADP and thromboxane A 2 (TxA 2 ). During aggregation the platelet response may demonstrate an initial increase in optical density as a result of shape change, followed by a primary, biphasic, sustained or reversible increase in light transmission [7] . The secretion of platelet ATP from the dense granules can be simultaneously monitored using luminescence by addition of luciferin-luciferase reagents. Measuring the secretion of dense granules is important in diagnosis of Hermansky-Pudlak syndrome (HPS) and other dense granule secretory and release disorders. However, a defect in ATP secretion cannot discriminate between abnormal granule formation or defects in platelet signaling, necessitating additional investigations such as electron microscopy, serotonin uptake and measurement of total platelet ATP/ADP content [4] . Although LTA is considered to be the reference standard method for the investigation of platelet function, the technique is time consuming, requires large blood volumes for preparation of PRP, needs to be performed on fresh samples and requires expertise for correct performance and interpretation [8] . Moreover, not all laboratories use light transmission lumiaggregometry (lumi-LTA), as a recent worldwide survey showed that 40.7% of laboratories use this for the diagnosis of inherited platelet function defects [9] .
Multiple electrode aggregometry (MEA) has recently been developed for rapid assessment of platelet function. The device evaluates platelet responses in disposable ready-to-use test cuvettes, each containing two pairs of electrodes enabling two simultaneous measurements. During the test activated platelets adhere onto the sensor wires, resulting in increased electrical resistance, which is continuously monitored and reported as the area under the curve (AUC). As a whole blood method, MEA only requires small blood volumes, making it possible for it to be used as a point-of-care test with standardized reagents. In addition, the use of whole blood offers the advantage of assessing platelet function under more physiological conditions and avoids the variables associated with the preparation of PRP [10] . Although MEA can also measure the kinetic changes in aggregation over time, including the parameters of lag time, slope and area under the curve and maximal aggregation, the traces are not as detailed as LTA, which not only measures these but also includes shape change, and primary (reversible) and secondary aggregation responses. In addition, MEA does not measure released ATP in parallel with aggregation. As MEA is becoming increasingly popular for measuring antiplatelet therapy and has been shown to be useful for detecting severe PFDs, we assessed the potential utility of MEA for detecting mild PFDs by comparison with the current reference standard, lumi-LTA, in participants recruited to the UK Genotyping and Phenotyping of Platelets (GAPP) study [11] .
Materials and methods

Participants
Between September 2013 and November 2015, a total of 149 individuals (109 patients and 40 controls) were evaluated and recruited into the GAPP study (www.birmingha m.ac.uk/plateletgapp) from nine UK Haemophilia Care Centres. All patients or their parents gave written informed consent in accordance with the GAPP project ethical approval (REC reference: 06/MRE07/36).
Reagents
ADP, ristocetin and adrenaline were purchased from Sigma (Poole, UK). Arachidonic acid and U46619 were purchased from Cayman Chemical Company (Ann Arbor, MI, USA). The PAR1 peptide (SFLLRN) was purchased from Severn Biotech (Kidderminster, UK). Collagen was purchased from Takeda (Linz, Austria) and luciferin luciferase reagent (Chrono-lume) was purchased from Chrono-log Corporation (Havertown, PA, USA). The reagents were dissolved in phosphate-buffered saline (PBS) at pH 7.4, stored as frozen aliquots, thawed and diluted in PBS when required and kept on ice. Collagen was stored as a concentrated stock at 1 mg mL À1 as supplied by the manufacturer at 4°C and diluted with the buffer provided.
Blood sampling
Whole blood (40 mL from adults and 20 mL from children) was obtained and anticoagulated with one-tenth volume of 0.109 mol L À1 buffered trisodium citrate in vacutainer plastic tubes (Becton Dickinson, Plymouth, UK). An additional 2-3 mL blood was anticoagulated with EDTA in vacutainer plastic tubes (Becton Dickinson). The same volume of blood was collected from a healthy control at the same time in each centre. Blood samples were immediately transported to the testing laboratory and assayed within 4 h (by MEA) and within 6 h (by lumi-LTA) from collection.
Blood sample preparation
PRP was prepared by centrifuging the citrated blood samples at 200 g for 20 min. PRP was transferred carefully into a 15-mL Falcon tube, capped and stored upright at room temperature. Platelet-poor plasma (PPP) was prepared by further centrifugation at 1000 9g for 10 min and transferred into a 15-mL Falcon tube, capped and stored upright at room temperature. About 2-3 mL of the buffy coat layer was also taken from the same tubes and stored at À80°C for DNA analysis.
Whole blood platelet counting using the Sysmex XN-1000 analyser EDTA blood samples from patients and controls were analyzed using the XN-1000 whole blood counter (Sysmex UK, Milton Keynes, UK). The XN-1000 is a state of the art whole blood analyzer that is capable of rapidly producing a full blood differential cell count from 88 ll of human blood. The analyzer has a set of unique platelet parameters, including three platelet counts, platelet impedance (PLT-I), platelet optical (PLT-O) and platelet fluorescence (PLT-F) count, platelet mean volume (MPV) and the immature platelet fraction (IPF). Platelet counts, MPV and IPF were recorded for each patient and compared against reference ranges established from 40 healthy normal controls. Quality assurance of the instrument was checked by an internal quality control using commercial fixed samples (Xn check, Sysmex UK) with known cell counts and testing samples provided by an external quality assessment scheme (UKNEQAS, Watford, UK).
Platelet counting of PRP
An impedance analyzer (Coulter Z2, Beckman Coulter, High Wycombe, UK) was used to count the platelets within the PRP by diluting 5 lL of PRP into 10 mL of fresh Isoton II diluent (Beckman Coulter). The platelets were counted in triplicate and the mean was calculated and recorded.
Platelet aggregation in whole blood
Whole blood impedance aggregometry was performed on citrated blood using MEA (Roche Diagnostics, Munich, Germany) consisting of 5 reaction channels, an integrated computer and guided automatic pipetting. The tests were performed in disposable ready-to-use test cells with two independent sensor units consisting of two silver-coated highly conductive copper electrodes (Roche Diagnostics).
In each test cuvette, mixed whole citrated blood (300 lL) was immediately diluted, 1 : 1 vol/vol, with 0.9% saline solution and incubated at 37°C for 3 min before addition of 30 ll of each agonist. Platelets were stimulated with a range of agonists, including ADP (10 and 2.5 lM), PAR-1 peptide (100 lM), collagen (1 and 3 lg mL À1 ) and arachidonic acid (0.5 mM). During the test, platelets adhere and aggregate upon the sensor electrode surfaces, resulting in an increase in the electrical resistance (impedance) and the signal recorded and plotted as an aggregometer trace. The total aggregation measured with this device is quantified as AUC or AU*min.
Platelet aggregation in platelet-rich plasma
Tests were carried out as described previously [7] . Aggregation studies were performed by using a dual Chrono-log lumiaggregometer (model ChronoLog 460 VS aggregometer, LabMedics, Abingdon on Thames, UK) in 400-lL mini cuvettes, stirred at 1200 rpm at 37°C. The 100% line was set using autologous platelet-poor plasma (PPP) and the 0% baseline established with native undiluted PRP. After 1 min platelets were stimulated with ADP (10, 30 and 100 lM), adrenaline (10, 30 and 100 lM), arachidonic acid (0.5, 1 and 1.5 mM), U46619 (1 and 3 lM), collagen (1 and 3 lg mL ). Platelet aggregation was monitored by measuring the change in optical density over 5 min after addition of the agonists and the maximal percentage of aggregation was recorded.
ATP secretion
ATP secretion from platelet dense granules was assessed simultaneously by lumi-LTA using the luciferase reagent (Chrono-lume); 30 lL of Luciferin reagent was added to the PRP and incubated for 1 min. Platelets were then stimulated with the agonists listed above and monitored for 5 min, followed by addition of 4 lL of an ATP standard (2 lM final concentration) to facilitate internal calibration. Secreted ATP levels were calculated by measuring the maximal amplitude of luminescence during the aggregation to a high dose of PAR-1 peptide (100 lM) and comparing it with the standard. A low cut-off point of 0.65 nmol ATP/10 8 platelets was established from previously studied healthy volunteers.
Statistical analysis
All control results were run on IBM SPSS Statistics version 22 (New York, NY, USA) and Graph Pad Prism version 7.0 software (GraphPad Software, La Jolla, CA, USA) to demonstrate the normal distribution and to obtain the mean and standard deviation values, which were then used to determine the cut-off values. Abnormal results by lumi-LTA were determined based on our previously published methodology, which is based upon both the magnitude and time course of response [7, 11] . The time course, including reversibility, is of particular importance. In contrast, because of the lack of these detailed kinetic changes detected by MEA, abnormal results were determined based on the cut-off values calculated as the 5th percentile of responses of normals to ADP 10 lM, collagen 1 lg mL
À1
, collagen 3 lg mL
, PAR1 100 lM and arachidonic acid 0.5 mM, which were 19.1, 21, 35.1, 42.3 and 19.7 (AUC), respectively.
Results
Overall comparison between MEA and lumi-LTA
We analyzed a total of 109 patients (21 male and 88 female) with a median age of 33 years (range 3-73) and 40 healthy adult volunteers (18-57 years) recruited into the GAPP study and compared MEA results with lumi-LTA. The overall hematological parameters and ATP secretion values of patients and healthy individuals are shown in Table 1 . Of 109 patients tested (Table 2) , 54 (49%) patients had abnormal responses by lumi-LTA to one or more agonists, as defined using previous criteria [11] . In contrast, only 16 (15%) patients were shown to have abnormal responses to one or more agonists by MEA, as defined using the cut-off values obtained from healthy individuals. The overall agreement between the two instruments is shown in Table 3 . Sixty-five out of 109 samples gave identical results by both tests, with the majority (52) giving normal responses. In contrast, there was disagreement in 44/109 samples. MEA detected an abnormality in three patients who were normal by lumi-LTA. However, 41 samples were normal by MEA but abnormal by lumi-LTA (Fig. 1) . In 12 (11%) patients with mild thrombocytopenia as characterized by low platelet count (< 150 9 10 9 L À1 ) in whole blood (Table 2) , abnormal aggregation responses were detected by lumi-LTA in eight patients and by MEA in six patients. In 20 patients with secretion defects characterized by reduced ATP levels (Table 2) , the lumi-LTA and MEA aggregation responses were abnormal in only eight and three patients, respectively. MEA is therefore less sensitive than lumi-LTA in detecting secretion defects, which is not surprising because MEA does not provide a direct readout of secretion.
Correlation between platelet counts and aggregation results by MEA and lumi-LTA
With MEA we found a significant but weak correlation between whole blood platelet counts and aggregation results in response to ADP 10 lM (r = 0.14, P = 0.016), but not with collagen 3 lg mL À1 (r = 0.072, P = 0.09), PAR-1 100 lM (r = 0.043, P = 0.19) or arachidonic acid (r = 0.15, P = 0.096) ( Figure S1 ). In contrast, with lumi-LTA, a weak correlation between the PRP counts and aggregation was only found in response to collagen 3 lg mL À1 (r = 0.13, P = 0.02), but not with ADP 10 lM (r = 0.025, P = 0.33), PAR-1 100 (r = 0.026, P = 0.32) or arachidonic acid 0.5 mM (r = 0.092, P = 0.22 ( Figure S2 ).
Analysis and identification of patients with various platelet function defects
Functional defects identified by lumi-LTA were classified into four main groups (Gi defect, secretion defects, COXlike defect and unclassified defects) according to their pattern of responses to specific agonists as previously described [11] . As shown in Fig. 2 , MEA only detected four out of 17 patients with Gi defects and two out of 20 with secretion defects. MEA only detected four out of seven patients with a COX-like defect and none out of four patients with unclassified defects by lumi-LTA. Finally, MEA gave abnormal responses to three samples out of six with multiple platelet defects.
Correlation between MEA and lumi-LTA with identical concentrations of agonists
To give a fairer comparison of the two tests, identical concentrations of the agonists ADP, collagen and PAR1 peptide were compared by both tests (with no ATP measurements included) and confirmed that MEA was still unable to detect some abnormalities detected by lumi-LTA: 16 (15%) vs. 41 (38%). Overall kappa statistics demonstrated only a fair agreement between MEA and lumi-LTA in response to ADP (k = 0.26, CI = 0.11-0.40) and collagen (k = 0.28, CI = 0.05-0.52) and a poor agreement in response to PAR1 (k = 0.07, CI = À0.17-0.32) (Fig. 3) .
Discussion
MEA performs platelet aggregation in whole blood and offers the advantage of assessing platelet function with more physiological conditions in small blood volumes and without sample processing [10] . As MEA is popular for measuring antiplatelet therapy and has been shown to be useful for detecting severe PFDs, we assessed the potential utility of MEA for detecting mild PFDs [12] [13] [14] [15] .
Comparison of the overall results in 109 patients with mild PFDs (Table 3) showed a moderate agreement between MEA and lumi-LTA, with the diagnosis being concordant in 60% of cases. The underlying genetic causes of these cases are yet to be confirmed by sequencing. Although MEA therefore gave a negative predictive value of 56%, in healthy individuals there was good agreement between MEA and lumi-LTA with no difference in response between identical concentrations of the agonists ADP, collagen and PAR-1 peptide (Fig. 3) . Our findings support a recent study by Seyfert et al., demonstrating equivalent results of MEA and lumi-LTA in healthy samples [16] . In patients' samples, however, we observed significant differences between the two techniques, with a fair to poor agreement between MEA and lumi-LTA with different agonists when overall results were analyzed using kappa statistics.
As MEA dilutes the whole blood 1 : 1 with saline, before testing we also investigated the influence of platelet counts (within normal ranges) on both MEA and lumi-LTA results. With MEA, a linear increase in aggregation responses with higher counts was only observed with ADP but not collagen, PAR-1 or arachidonic acid. In contrast, with lumi-LTA this was only observed with collagen but not ADP, PAR-1 or arachidonic acid (see supplementary figures). Previous studies with lumi-LTA have found no correlation between platelet count and aggregation results [7, [16] [17] [18] . Seyfert et al. also found a significant correlation between platelet count and platelet aggregation using MEA induced by ADP and collagen, but not by arachidonic acid [16] . Mengistu LTA aggregation (%) 0 C o n t r o l s P a t i e n t s C o n t r o l s P a t i e n t s blood aggregometry at lower platelet concentrations [19, 20] . Two more studies also reported correlations between platelet count and extent of platelet aggregation on MEA [18, 21] . However, the latter results are difficult to interpret as the counts were adjusted either by addition of PPP [21] , which is known to inhibit platelet aggregation [17] , or with dilution with Tyrode's buffer [18] .
We found that MEA also detected more patients classified with COX-1-like defects than those with Gi and secretion defects. This suggests that MEA may be more sensitive in response to defects in the thromboxane pathway. However, the lack of sensitivity of MEA in detecting Gi defects may also be related to the higher ADP concentration (10 lM) used in this study, which is slightly higher than the standard recommended concentration (6.5 lM). Interestingly, we have also observed that MEA showed high consistency in detecting abnormalities in patients with dual defects. These findings support the earlier reports suggesting that MEA is reliable in detecting more severe forms of platelet defects such as GT [12, 13] .
Measurement of secreted ATP levels is an additional but important tool in identifying patients with platelet secretion defects [22] . Indeed, the Chronolog whole blood aggregometer can also be used in conjunction with ATP secretion [23] . Moreover, it is well known that individuals with reduced dense granule secretion can often demonstrate normal aggregation responses [11] . In this study MEA and lumi-LTA gave normal responses in 17 (85%) and 12 (60%) patients, respectively, who were found to have low secreted ATP levels. This is probably unsurprising given that MEA does not directly measure ATP secretion and the aggregation responses are probably less sensitive at detecting the feedback loop from released ATP/ADP from the dense granules.
Hirudin is the anticoagulant of choice for MEA recommended by the manufacturer [10] . Previous studies have shown that different anticoagulants can affect platelet function activity [24] . In this study we only used citrated blood for both techniques in order to have a similar comparison with identical levels of free calcium. Furthermore, a study using citrated blood from healthy individuals showed no significant difference between MEA and LTA even at higher citrate concentrations [16] . Storage time between blood collection and sample processing is a crucial factor when testing platelet activity, particularly with whole blood aggregometry. To avoid variation of results because of time delays, MEA was always tested during PRP/PPP preparation for LTA to ensure that the analysis was always completed rapidly within 4 h [16, 25] . Bar charts show the number of patients with various platelet function defects detected by light transmission lumi-aggregometry (lumi-LTA) (black) and multiple electrode aggregometry (MEA) (grey) The response to each agonist was considered to be abnormal (on MEA) when it fell below the cut-off value that was set from healthy individuals and (on lumi-LTA) as defined using previously published criteria [11] . 
Study limitations
Our study was performed using only trisodium citrate anticoagulant in blood samples tested by LTA and MEA. The study was also performed on individuals with suspected mild platelet defects with a bleeding history. It would be of interest to fully investigate the utility of MEA in patients with a defined set of pre-diagnosed platelet function disorders. ADP was also used at a higher concentration of 10 lM above the recommended concentration of 6.5 lM for MEA and may have contributed to the lack of sensitivity observed.
Conclusions
Overall, MEA demonstrates a lack of sensitivity in identifying patients with mild bleeding associated with abnormal platelet function and platelet secretion defects. More studies are required to further evaluate the role of MEA in the diagnosis of bleeding disorders.
Addendum
R. Al Ghaithi performed research, analyzed data and wrote the paper; S. Drake performed research and analyzed data; S. P. Watson designed the research and contributed to writing the paper; N. V. Morgan designed the research and contributed to writing the paper; and P.
Harrison designed the research, analyzed data and contributed to writing the paper. 
